[{"indications": "Indications\u00a0see under Dose", "name": "CALCITONIN (SALMON)/SALCATONIN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.6 Drugs affecting bone metabolism", "6.6.1 Calcitonin and parathyroid hormone"], "cautions": "Cautions\u00a0history of allergy (skin test advised); heart failure", "side-effects": "Side-effects\u00a0nausea, vomiting, diarrhoea, abdominal pain; flushing;\r\ndizziness, headache, taste disturbances; musculoskeletal pain; with\r\nnasal spray nose and throat irritation, rhinitis, sinusitis and epistaxis; less commonly diuresis, oedema, cough, visual disturbances,\r\ninjection-site reactions, rash, hypersensitivity reactions including\r\npruritus", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4443.htm", "doses": ["Hypercalcaemia of malignancy (see also section 9.5.1.2), adult over 18 years, by subcutaneous or intramuscular injection, 100\u00a0units\r\nevery 6\u20138 hours adjusted according to response; max. 400\u00a0units every\r\n6\u20138 hours; in severe or emergency cases, by intravenous infusion, up to 10\u00a0units/kg over at least 6 hours", "Paget\u2019s disease of bone, adult over 18 years, by subcutaneous or intramuscular injection, 50\u00a0units 3 times weekly to\r\n100\u00a0units daily adjusted according to response", "Postmenopausal osteoporosis to reduce risk of vertebral fractures, intranasally, 200\u00a0units (1 spray) into one nostril daily,\r\nwith dietary calcium and vitamin D supplements (section 9.5.1.1 and section\r\n9.6.4)", "Prevention of acute bone loss due to sudden immobility, adult over 18 years, by subcutaneous or intramuscular injection, 100\u00a0units\r\ndaily in 1\u20132 divided doses for 2\u20134 weeks, reduced to 50\u00a0units daily\r\nat start of mobilisation and continued until fully mobile"], "pregnancy": "Pregnancy\u00a0avoid unless potential benefit outweighs risk (toxicity\r\nin animal studies)"}]